393 related articles for article (PubMed ID: 31332070)
21. Loss and gain of ceftazidime-avibactam susceptibility in a non-carbapenemase-producing K1-ST23 hypervirulent
Zhao J; Pu D; Li Z; Zhang Y; Liu X; Zhuo X; Lu B; Cao B
Virulence; 2024 Dec; 15(1):2348251. PubMed ID: 38697754
[TBL] [Abstract][Full Text] [Related]
22. Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2.
Hemarajata P; Humphries RM
J Antimicrob Chemother; 2019 May; 74(5):1241-1243. PubMed ID: 30753572
[TBL] [Abstract][Full Text] [Related]
23. Resistance to Ceftazidime-Avibactam in Klebsiella pneumoniae Due to Porin Mutations and the Increased Expression of KPC-3.
Humphries RM; Hemarajata P
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28396547
[No Abstract] [Full Text] [Related]
24. In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase.
Livermore DM; Warner M; Jamrozy D; Mushtaq S; Nichols WW; Mustafa N; Woodford N
Antimicrob Agents Chemother; 2015 Sep; 59(9):5324-30. PubMed ID: 26100712
[TBL] [Abstract][Full Text] [Related]
25. Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing
Ojdana D; Gutowska A; Sacha P; Majewski P; Wieczorek P; Tryniszewska E
Microb Drug Resist; 2019 Nov; 25(9):1357-1364. PubMed ID: 31295055
[TBL] [Abstract][Full Text] [Related]
26. KPC-50 Confers Resistance to Ceftazidime-Avibactam Associated with Reduced Carbapenemase Activity.
Poirel L; Vuillemin X; Juhas M; Masseron A; Bechtel-Grosch U; Tiziani S; Mancini S; Nordmann P
Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32457107
[TBL] [Abstract][Full Text] [Related]
27. Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview.
Hobson CA; Pierrat G; Tenaillon O; Bonacorsi S; Bercot B; Jaouen E; Jacquier H; Birgy A
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0044722. PubMed ID: 35980232
[TBL] [Abstract][Full Text] [Related]
28. Evolution of
Won EJ; Park K; Jeong YS; Kim J; Choi Y; Kim SH; Kim MN; Sung H
J Korean Med Sci; 2024 Jul; 39(25):e208. PubMed ID: 38952349
[TBL] [Abstract][Full Text] [Related]
29. Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in
Giddins MJ; Macesic N; Annavajhala MK; Stump S; Khan S; McConville TH; Mehta M; Gomez-Simmonds A; Uhlemann AC
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263067
[TBL] [Abstract][Full Text] [Related]
30. Global Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam.
Kazmierczak KM; Biedenbach DJ; Hackel M; Rabine S; de Jonge BL; Bouchillon SK; Sahm DF; Bradford PA
Antimicrob Agents Chemother; 2016 Aug; 60(8):4490-500. PubMed ID: 27161636
[TBL] [Abstract][Full Text] [Related]
31. Potency of Vaborbactam Is Less Affected than That of Avibactam in Strains Producing KPC-2 Mutations That Confer Resistance to Ceftazidime-Avibactam.
Tsivkovski R; Lomovskaya O
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015028
[TBL] [Abstract][Full Text] [Related]
32. Mutations in
Haidar G; Clancy CJ; Shields RK; Hao B; Cheng S; Nguyen MH
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223379
[TBL] [Abstract][Full Text] [Related]
33. In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016.
Galani I; Souli M; Nafplioti K; Adamou P; Karaiskos I; Giamarellou H; Antoniadou A;
Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1143-1150. PubMed ID: 30825054
[TBL] [Abstract][Full Text] [Related]
34. Genomic characterization of a Klebsiella pneumoniae ST1519 resistant to ceftazidime/avibactam carrying a novel KPC variant (KPC-36).
Gaibani P; Ambretti S; Campoli C; Viale P; Re MC
Int J Antimicrob Agents; 2020 Jan; 55(1):105816. PubMed ID: 31593765
[No Abstract] [Full Text] [Related]
35. Emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in KPC-2-producing Klebsiella pneumoniae of sequence type 39 during treatment.
Galani I; Karaiskos I; Angelidis E; Papoutsaki V; Galani L; Souli M; Antoniadou A; Giamarellou H
Eur J Clin Microbiol Infect Dis; 2021 Jan; 40(1):219-224. PubMed ID: 32729059
[TBL] [Abstract][Full Text] [Related]
36. Ceftazidime-Avibactam Resistance Associated with Increased
Coppi M; Di Pilato V; Monaco F; Giani T; Conaldi PG; Rossolini GM
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964792
[TBL] [Abstract][Full Text] [Related]
37. Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.
Haidar G; Clancy CJ; Chen L; Samanta P; Shields RK; Kreiswirth BN; Nguyen MH
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630202
[TBL] [Abstract][Full Text] [Related]
38. Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization.
Gaibani P; Re MC; Campoli C; Viale PL; Ambretti S
Clin Microbiol Infect; 2020 Apr; 26(4):516.e1-516.e4. PubMed ID: 31740422
[
